| Prespecified dose-response analysis for a very early rehabilitation trial (AVERT) J Bernhardt, L Churilov, F Ellery, J Collier, J Chamberlain, P Langhorne, ... Neurology 86 (23), 2138-2145, 2016 | 252 | 2016 |
| Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection … CDA Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A ... The Lancet 381 (9883), 2091-9, 2013 | 186* | 2013 |
| Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort WP Law, CJ Duncombe, A Mahanontharit, MA Boyd, K Ruxrungtham, ... Aids 18 (8), 1169-1177, 2004 | 186 | 2004 |
| Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 WP Law, GJ Dore, CJ Duncombe, A Mahanontharit, MA Boyd, ... Aids 17 (15), 2191-2199, 2003 | 165 | 2003 |
| Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps MA Boyd, M Boffito, A Castagna, V Estrada HIV medicine 20, 3-11, 2019 | 118 | 2019 |
| Long-term survival in HIV positive patients with up to 15 years of antiretroviral therapy H McManus, CC O'Connor, M Boyd, J Broom, D Russell, K Watson, ... PloS one 7 (11), e48839, 2012 | 101 | 2012 |
| Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis MA Boyd, CL Moore, JM Molina, R Wood, JS Madero, M Wolff, ... The lancet HIV 2 (2), e42-e51, 2015 | 90 | 2015 |
| Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir MA Boyd, P Srasuebkul, K Ruxrungtham, PI Mackenzie, V Uchaipichat, ... Pharmacogenetics and genomics 16 (5), 321-329, 2006 | 83 | 2006 |
| Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency virus … AJ Stockdale, MJ Saunders, MA Boyd, LJ Bonnett, V Johnston, ... Clinical infectious diseases 66 (12), 1846-1857, 2018 | 79 | 2018 |
| Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients D Burger, M Boyd, C Duncombe, M Felderhof, A Mahanontharit, ... Journal of antimicrobial chemotherapy 51 (5), 1231-1238, 2003 | 73 | 2003 |
| Improvements in antiretroviral therapy outcomes over calendar time MA Boyd Current Opinion in HIV and AIDS 4 (3), 194-199, 2009 | 71 | 2009 |
| Pandemic influenza: clinical issues M Boyd, K Clezy, R Lindley, R Pearce Medical journal of Australia 185 (S10), S44-S47, 2006 | 71 | 2006 |
| Intensification of Antiretroviral Therapy With Raltegravir or Addition of Hyperimmune Bovine Colostrum in HIV-Infected Patients With Suboptimal CD4+ T-Cell … H Byakwaga, M Kelly, DFJ Purcell, MA French, J Amin, SR Lewin, ... Journal of Infectious Diseases 204 (10), 1532-1540, 2011 | 70 | 2011 |
| Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis AC Achhra, G Mwasakifwa, J Amin, MA Boyd The Lancet HIV 3 (8), e351-e360, 2016 | 69 | 2016 |
| Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines E Wright, A Grulich, K Roy, M Boyd, V Cornelisse, D Russell, D O'Donnell, ... Journal of virus eradication 3 (3), 168-184, 2017 | 65 | 2017 |
| Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis A Lau, FYS Kong, CK Fairley, DJ Templeton, J Amin, S Phillips, M Law, ... New England Journal of Medicine 384 (25), 2418-2427, 2021 | 62 | 2021 |
| Australasian society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018 E Wright, A Grulich, K Roy, M Boyd, V Cornelisse, D Russell, D O'Donnell, ... Journal of virus eradication 4 (3), 143-159, 2018 | 62 | 2018 |
| Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials D Carey, J Amin, M Boyd, K Petoumenos, S Emery Journal of Antimicrobial Chemotherapy 65 (9), 1878-1888, 2010 | 58 | 2010 |
| Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research MA Boyd, DA Cooper Aids 21, S55-S63, 2007 | 57 | 2007 |
| Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients M Boyd, P Mootsikapun, D Burger, T Chuenyam, S Ubolyam, ... Antiviral therapy 10 (2), 301-307, 2005 | 56 | 2005 |
Chris DuncombeSenioe Program Officer Bill and Melinda Gates FoundationVerified email at gatesfoundation.org
